The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors.
Open accessAbstract
SR 49059, a new potent and selective orally active, nonpeptide vasopressin (AVP) antagonist has been characterized in several in vitro and in vivo models. SR 49059 showed high affinity for V1a receptors from rat liver (Ki = 1.6 +/- 0.2) and human platelets, adrenals, and myometrium (Ki ranging from 1.1 to 6.3 nM). The previously described nonpeptide V1 antagonist, OPC-21268, was almost inactive in human tissues at concentrations up to 100 microM. SR 49059 exhibited much lower affinity (two orders of magnitude or more) for AVP V2 (bovine and human), V1b (human), and oxytocin (rat and human) receptors and had no measurable affinity for a great number of other receptors. In vitro, AVP-induced contraction of rat caudal artery was competitively antagonized by SR 49059 (pA2 = 9.42). Furthermore, SR 49059 inhibited AVP-induced human platelet aggregation with an IC50 value of 3.7 +/- 0.4 nM, while OPC-21268 was inactive up to 20 microM. In vivo, SR 49059 inhibited the pressor response to exogenous AVP in pithed rats (intravenous) and in conscious normotensive rats (intravenous and per os) with a long duration of action (> 8 h at 10 mg/kg p.o). In all the biological assays used, SR 49059 was devoid of any intrinsic agonistic activity. Thus, SR 49059 is the most potent and selective nonpeptide AVP V1a antagonist described so far, with marked affinity, selectivity, and efficacy toward both animal and human receptors. With this original profile, SR 49059 constitutes a powerful tool for exploring the therapeutical usefulness of a selective V1a antagonist.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922
LIGAND: A versatile computerized approach for characterization of ligand-binding systems
Munson, P. J., & Rodbard, D. (1980) · Analytical Biochemistry · doi:10.1016/0003-2697(80)90515-1 · Cited by 8,429
SOME QUANTITATIVE USES OF DRUG ANTAGONISTS
ARUNLAKSHANA, O., & SCHILD, H. O. (1959) · British Journal of Pharmacology and Chemotherapy · doi:10.1111/j.1476-5381.1959.tb00928.x · Cited by 3,938
The aggregation of blood platelets
Born, G. V. R., & Cross, M. J. (1963) · The Journal of Physiology · doi:10.1113/jphysiol.1963.sp007185 · Cited by 2,111
Structure and expression of a human oxytocin receptor
Kimura, T., Tanizawa, O., Mori, K., Brownstein, M. J., & Okayama, H. (1992) · Nature · doi:10.1038/356526a0 · Cited by 632
Molecular cloning of the receptor for human antidiuretic hormone
Birnbaumer, M., Seibold, A., Gilbert, S., Ishido, M., Barberis, C., Antaramian, A., Brabet, P., & Rosenthal, W. (1992) · Nature · doi:10.1038/357333a0 · Cited by 546
Lolait, S. J., O'Carroll, A.-M., McBride, O. W., Konig, M., Morel, A., & Brownstein, M. J. (1992) · Nature · doi:10.1038/357336a0 · Cited by 524 · cited 1×
“Determination of the amino acid sequence of human (4) and rat (5) V2 receptors, rat Via AVP receptors (6), and human oxytocin (OT)' receptors (7) clearly confirms that the receptors for neurohypophysial peptides constitute a subfamily of Gprotein-coupled membrane receptors.”
BackgroundMolecular cloning and expression of a rat Via arginine vasopressin receptor
Morel, A., O'Carroll, A.-M., Brownstein, M. J., & Lolaft, S. J. (1992) · Nature · doi:10.1038/356523a0 · Cited by 477
Subclasses of angiotensin II binding sites and their functional significance.
Dudley, D. T., Panek, R. L., Major, T. C., Lu, G. H., Bruns, R. F., Klinkefus, B. A., Hodges, J. C., & Weishaar, R. E. (1990) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09488-x · Cited by 374
Molecular identification of the gene responsible for congenital nephrogenic diabetes insipidus
Rosenthal, W., Seibold, A., Antaramian, A., Lonergan, M., Arthus, M.-F., Hendy, G. N., Birnbaumer, M., & Bichet, D. G. (1992) · Nature · doi:10.1038/359233a0 · Cited by 333
Cited by
Oxytocin and Vasopressin Agonists and Antagonists as Research Tools and Potential Therapeutics
Manning, M., Misicka, A., Olma, A., Bankowski, K., Stoev, S., Chini, B., Durroux, T., Mouillac, B., Corbani, M., & Guillon, G. (2012) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2012.02303.x · Cited by 423
Non-peptide arginine-vasopressin antagonists: the vaptans
Decaux, G., Soupart, A., & Vassart, G. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60695-9 · Cited by 376
Yamamura, Y., Nakamura, S., Itoh, S., Hirano, T., Onogawa, T., Yamashita, T., Yamada, Y., Tsujimae, K., Aoyama, M., Kotosai, K., et al. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37873-5 · Cited by 337
MANNING, M., STOEV, S., CHINI, B., DURROUX, T., MOUILLAC, B., & GUILLON, G. (2008) · Progress in Brain Research · doi:10.1016/s0079-6123(08)00437-8 · Cited by 296
The Binding Site of Neuropeptide Vasopressin V1a Receptor
Mouillac, B., Chini, B., Balestre, M.-N., Elands, J., Trumpp-Kallmeyer, S., Hoflack, J., Hibert, M., Jard, S., & Barberis, C. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.43.25771 · Cited by 262
Gal, C. S.-L., Wagnon, J., Simiand, J., Griebel, G., Lacour, C., Guillon, G., Barberis, C., Brossard, G., Soubrié, P., Nisato, D., et al. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.3.1122 · Cited by 211
Self-citationFreeman, S. M., & Young, L. J. (2016) · Journal of Neuroendocrinology · doi:10.1111/jne.12382 · Cited by 196
“There are now several highly selective, low molecular weight, nonpeptide ligands that purportedly cross the blood-brain barrier, such as the selective human AVPR1a antagonist, SR49059 (90), and the selective human OXTR antagonist, ALS-II-69 (91,92).”
BackgroundFreeman, S. M., Inoue, K., Smith, A. L., Goodman, M. M., & Young, L. J. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.03.023 · Cited by 185
“…ligands that were developed specifically for use in human tissue for their ability to displace radioligand binding to hOXTR and hAVPR1A: a novel OXTR antagonist developed in our lab (ALS-II-69; Smith et al., 2013) and an AVPR1A antagonist developed by Sanofi Recherche (SR49059; Gal et al., 1993).”
BackgroundFreeman, S. M., Walum, H., Inoue, K., Smith, A. L., Goodman, M. M., Bales, K. L., & Young, L. J. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.04.055 · Cited by 153
The Basic and Clinical Pharmacology of Nonpeptide Vasopressin Receptor Antagonists
Thibonnier, M., Coles, P., Thibonnier, A., & Shoham, M. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.175 · Cited by 146
Åkerlund, M., Bossmar, T., Brouard, R., Kostrzewska, A., Laudanski, T., Lemancewicz, A., Gal, C. S., & Steinwall, M. (1999) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1999.tb08112.x · Cited by 123
Self-citationOshikawa, S., Tanoue, A., Koshimizu, T.-A., Kitagawa, Y., & Tsujimoto, G. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.3.623 · Cited by 105
“In addition, SSR149415 is more than 100 times more selective for V1b over OT receptors (Serradeil-Le Gal et al., 2002a), and AVP-induced insulin secretion was totally blunted in the V1b-KO mice.”
BackgroundInfluentialFreeman, S. M., Palumbo, M. C., Lawrence, R. H., Smith, A. L., Goodman, M. M., & Bales, K. L. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0315-3 · Cited by 82
Molecular biology of vasopressin receptors
LOLAIT, S. J., O'CARROLL, A., & BROWNSTEIN, M. J. (1995) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1995.tb44688.x · Cited by 87
Hicks, C., Ramos, L., Reekie, T., Misagh, G. H., Narlawar, R., Kassiou, M., & McGregor, I. S. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12613 · Cited by 76
Qiu, F., Qiu, C., Cai, H., Liu, T., Qu, Z., Yang, Z., Li, J., Zhou, Q., & Hu, W. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12635 · Cited by 67
Gupta, J., Russell, R. J., Wayman, C. P., Hurley, D., & Jackson, V. M. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.226 · Cited by 66
“As the oxytocin and the V1A antagonist used are reported to be competitive antagonists (L-368899 Pettibone et al., 2004; SR49059 Serradeil-Le Gal et al., 1993) where only a single or two high concentrations of antagonist were effective, the Gaddum equation (pKB¼ log (concentration ratio 1) log (antagonist concentratio…”
BackgroundMethodInfluentialFolny, V., Raufaste, D., Lukovic, L., Pouzet, B., Rochard, P., Pascal, M., & Serradeil-Le Gal, C. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00148.2003 · Cited by 61
Oxytocin and vasopressin modulate the social response to threat: a preclinical study
Bowen, M. T., & McGregor, I. S. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000388 · Cited by 63
Selective localization of oxytocin receptors and vasopressin 1a receptors in the human brainstem
Freeman, S. M., Smith, A. L., Goodman, M. M., & Bales, K. L. (2017) · Social Neuroscience · doi:10.1080/17470919.2016.1156570 · Cited by 51
“Adjacent sections for each of the two radioligands were incubated in the following four conditions: (1) radioligand alone, (2) radioligand plus 10 nM of the AVPR1a selective antagonist SR49059 (Gal et al., 1993), (3) radioligand plus 100 nM of the OXTR selective antagonist ALS-II-69, or (4) radioligand plus 1 μM of AL…”
MethodInfluentialKawamata, M., Mitsui-Saito, M., Kimura, T., Takayanagi, Y., Yanagisawa, T., & Nishimori, K. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01914-9 · Cited by 47
Nicou, A., Serrière, V., Prigent, S., Boucherie, S., Combettes, L., Guillon, G., Alonso, G., & Tordjmann, T. (2003) · The FASEB Journal · doi:10.1096/fj.03-0082fje · Cited by 38
Gal, C. S.-L., Raufaste, D., Derick, S., Blankenstein, J., Allen, J., Pouzet, B., Pascal, M., Wagnon, J., & Ventura, M. A. (2007) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00062.2007 · Cited by 35
Self-citationThibonnier, M., Coles, P., Conarty, D. M., Plesnicher, C. L., & Shoham, M. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39056-1 · Cited by 35
Gillard, E. R., Coburn, C. G., de Leon, A., Snissarenko, E. P., Bauce, L. G., Pittman, Q. J., Hou, B., & Currás-Collazo, M. C. (2007) · Endocrinology · doi:10.1210/en.2006-0995 · Cited by 34
Hawtin, S. R., Wesley, V. J., Parslow, R. A., Patel, S., & Wheatley, M. (2000) · Biochemistry · doi:10.1021/bi0013400 · Cited by 32
Ramos, L., Hicks, C., Caminer, A., Couto, K., Narlawar, R., Kassiou, M., & McGregor, I. S. (2016) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2016.10.002 · Cited by 25
Hawtin, S. R., Wesley, V. J., Simms, J., Argent, C. C. H., Latif, K., & Wheatley, M. (2005) · Molecular Endocrinology · doi:10.1210/me.2005-0148 · Cited by 24
Hicks, C., Ramos, L., Reekie, T. A., Narlawar, R., Kassiou, M., & McGregor, I. S. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3902-5 · Cited by 23
Hicks, C., Ramos, L., Dampney, B., Baracz, S. J., McGregor, I. S., & Hunt, G. E. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.10.005 · Cited by 22
Metadata
- Authors
- Serradeil-Le Gal, C., Wagnon, J., Garcia, C., Lacour, C., Guiraudou, P., Christophe, B., Villanova, G., Nisato, D., Maffrand, J. P., & Le Fur, G.
- Venue
- Journal of Clinical Investigation
- Published
- 1993-07-01
- Volume
- 92
- Issue
- 1
- Pages
- 224-231
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2027467507
- Cited by
- 270
- References
- 29
- FWCI
- 7.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.